GlassScriptPhysician profile
Syed A Imam
NPI 1144413733
$3,345.79
in general payments reported to CMS, 2019-2025
15 companies · $14.86 in 2025
The $14.86 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2022: $1,434 · 2023: $1,103 · 2024: $265 · 2025: $14.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $610.69 | 2019-2023 | Spravato |
| Abbvie INC. | $475.78 | 2022-2023 | |
| Alkermes, INC. | $396.19 | 2019-2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $350.72 | 2019-2023 | Ingrezza |
| Neos Therapeutics, LP | $272.77 | 2022-2023 | Adzenys Xr-Odt |
| Corium, LLC | $252.47 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $232.19 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $182.61 | 2022-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.32 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $167.72 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $110.82 | 2019 | |
| Almatica Pharma LLC | $44.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.13 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $27.64 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.